Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the mRNA Therapeutics CDMO Market Heading Into 2029?

In the past few years, there’s been substantial expansion in the mRNA therapeutics CDMO market. The market size is set to escalate from $4.24 billion in 2024 to $4.74 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.0%. Factors behind the growth during the historic period include increased demand for swift vaccine development, enhanced public and private investment in mRNA research, a surge in frequency of infectious diseases, expansion of pharmaceutical outsourcing practices, along with a heightened global emphasis on readiness for pandemics.

In the coming years, a swift expansion is anticipated in the mRNA therapeutics CDMO market, with its valuation projected to reach $7.40 billion by 2029, witnessing a compound annual growth rate of 11.8%. The escalation predicted in the forecast period is due to increased attention towards personalized medicine, heightened need for fast-response platforms to combat emerging diseases, growth in health spending in emerging regions, government incentives to accelerate domestic production, and rising interest in non-infectious disease applications. The major trends expected during the prognosis period include progress in lipid nanoparticle delivery technologies, a surge in automation in the production processes, widening acceptance of modular and ongoing manufacturing platforms, enhancement of cold chain logistics infrastructure, and an increasing adoption of artificial intelligence for process optimization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25841&type=smp

Which Factors Are Pushing The mRNA Therapeutics CDMO Market Forward?

The rising incidence of chronic and infectious ailments is projected to stimulate the mRNA therapeutics CDMO market’s expansion. These encompass enduring health conditions like diabetes, heart disorders, and asthma, and diseases triggered by pathogenic microorganisms, including viruses, bacteria, and parasites, that can transmit directly or indirectly among people. The prevalence of these illnesses is magnified due to aging populations, which are more vulnerable to long-term afflictions and infections. mRNA therapeutics CDMO contributes to tackling such diseases by offering comprehensive development and fabrication services that expedite the delivery of specific, personalized mRNA remedies to patients. For example, Allergy UK, a national charity based in the UK, reported in April 2024 that allergies afflict more than 21 million individuals in the UK. This emerged as the most frequently reported chronic health condition in 2022, and forecasts suggest that half of Europe’s population will suffer from at least one allergy by 2026. Consequently, the escalating burden of chronic and infectious diseases propels the advancement of the mRNA therapeutics CDMO market.

Which Segment Held The Largest Share In The mRNA Therapeutics CDMO Market In 2025?

The mrna therapeutics cdmo market covered in this report is segmented –

1) By Type Of Service: Development Services, Manufacturing Services, Laboratory Services

2) By Indication: Infectious Diseases, Metabolic And Genetic Diseases, Cardiovascular And Cerebrovascular Diseases

3) By Application: Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies

4) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations

Subsegments:

1) By Development Services: Process Development, Analytical Method Development, Formulation Development, Regulatory Support

2) By Manufacturing Services: Plasmid DNA Manufacturing, mRNA Synthesis, Lipid Nanoparticle (LNP) Formulation, Fill-Finish Services

3) By Laboratory Services: Quality Control Testing, Stability Testing, Bioanalytical Testing, Preclinical Testing

Which Trends Are Redefining The Future Landscape Of The mRNA Therapeutics CDMO Industry?

Major corporations within the mRNA therapeutics CDMO market are concentrating their efforts on creating ground-breaking solutions like in situ nanomedicine vaccines. The aim is to amplify the precision and effectiveness of mRNA-based vaccines through targeted immune stimulation. In situ nanomedicine vaccines are a new wave of mRNA-based treatments devised to produce nanomedicines inside the patient’s body. This aids in targeted delivery and personalized immune activation through controlled transgene expression. For instance, Esphera SynBio Inc., a biotechnology business based in Canada, introduced a new initiative in January 2025 with support from the CQDM Quantum Leap program. The purpose of this project is to improve original lipid nanoparticle or messenger RNA (LNP/mRNA) vaccines using unique transgene designs that set off the in vivo production of immunostimulatory nanomedicines. This tactic allows accurate antigen delivery and specifically designed immune responses, setting up the technology as a possible game-changer in vaccine innovation.

Which Organizations Are Driving Progress In The mRNA Therapeutics CDMO Industry?

Major companies operating in the mrna therapeutics cdmo market are Sanofi SA, Thermo Fisher Scientific Inc., Boehringer Ingelheim, Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, BioNTech SE, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Novo Holdings AS, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., CureVac SE, TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG, RiboPro

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-cdmo-global-market-report

Which Region Is Expected To Experience The Highest Growth In The mRNA Therapeutics CDMO Industry?

North America was the largest region in the mRNA therapeutics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25841&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model